Abstract
Natural products are a promising source for the development of novel cancer therapies, due to their potential effectiveness and low toxicity profiles. As a main component of Herba oxytropis, 2',4'-dihydroxychalcone (TFC) is known to demonstrate anti-tumor activity in vitro. In the present study, TFC was found to potently inhibit proliferation and induce apoptosis in PC-3 human prostate cancer cells in a dose-dependent manner. The results demonstrated that the induction of apoptosis is associated with cell cycle arrest at the G0/G1 phase and activation of caspase-3/-7. Additional mechanistic studies of two biomarkers, phosphatase and tensin homolog (PTEN) and cyclin-dependent kinase inhibitor 1B (p27(Kip1)), in prostate cancer revealed that TFC treatment significantly upregulated the expression of PTEN and p27(Kip1). The findings of the present study indicate that TFC-induced apoptosis in PC-3 cells via upregulation of PTEN and p27(Kip1), which results in cell cycle arrest in G0/G1 phase, activation of caspase-3/-7 and induction of apoptosis. Therefore, TFC may be a potential compound for human prostate cancer therapy.
References
Nov 4, 1994·Cell·J Y KatoC J Sherr
Feb 25, 1998·The Journal of Urology·R M YangR E Reiter
Sep 10, 1998·Journal of the National Cancer Institute·C Cordon-CardoH I Scher
Apr 14, 1999·Cell Death and Differentiation·A G Porter, R U Jänicke
Aug 24, 1999·Cancer Metastasis Reviews·E Macri, M Loda
Mar 16, 2001·Current Biology : CB·R MamillapalliH Sun
Nov 27, 2001·Bioorganic & Medicinal Chemistry Letters·C PougetA J Chulia
Jan 25, 2002·Annals of the New York Academy of Sciences·O W BrawleyH Parnes
Apr 18, 2003·The Journal of Biological Chemistry·Xiao-Feng LeRobert C Bast
Jan 30, 2004·Proceedings of the National Academy of Sciences of the United States of America·Stéphanie A BackmanTak W Mak
Jul 12, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·James A Crowell
Oct 29, 2005·Planta medica·Jih-Jung ChenIh-Sheng Chen
Aug 30, 2008·Sub-cellular Biochemistry·Sahar A SaddoughiBesim Ogretmen
May 22, 2009·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Chenghua LouBaochang Cai
May 18, 2010·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Chenghua LouBaochang Cai
Sep 23, 2010·European Journal of Pharmacology·R Vidya PriyadarsiniS Nagini
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Sep 29, 2011·Journal of Experimental & Clinical Cancer Research : CR·Rebecca S Y Wong
Dec 17, 2011·Current Molecular Medicine·Y WangM Liu
Jun 5, 2012·Frontiers in Endocrinology·Yanqiu LiuShidong Jia
Sep 14, 2012·Expert Opinion on Therapeutic Patents·Sônia S CostaFrederico A Vanderlinde
Jul 24, 2013·Planta medica·Rongcai YueWeidong Zhang
Nov 29, 2013·International Journal of Molecular Sciences·Feng XieLiqun Zhou
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Citations
Mar 2, 2019·Natural Product Research·Mei-Rong ZhangYan-Ping Shi
Mar 29, 2018·Endocrinology and Metabolism·Chan Ho ParkEun Sook Kim
Sep 1, 2017·Drug Delivery·Min ZhouSanjun Shi
Oct 18, 2016·Drug Delivery·Shouwen ZhangJin Pan
May 18, 2016·Journal of Liposome Research·Rui-Xi HeWei-Dong Chen
Jun 27, 2017·Nanoscale·Xuan LiLijian Jin
Oct 6, 2020·Expert Opinion on Drug Delivery·Khushwant S YadavAmbikanandan Misra
Oct 24, 2020·Drug Development and Industrial Pharmacy·Qiping ZengJinshan Chen